These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNITED STATES
|
||||
|
SECURITIES AND EXCHANGE COMMISSION
|
||||
|
Washington, D.C. 20549
|
||||
|
|
|
|
||
|
FORM 10-Q
|
||||
|
(Mark One)
|
|
|||
|
Q
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|||
|
For the quarterly period ended September 30, 2015
|
||||
|
OR
|
||||
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|||
|
|
||||
|
For the transition period from ________________ to ______________
|
||||
|
|
||||
|
Commission File Number: 001-14273
|
||||
|
|
||||
|
CORE LABORATORIES N.V.
|
||||
|
(Exact name of registrant as specified in its charter)
|
||||
|
|
||||
|
The Netherlands
|
Not Applicable
|
|||
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
|||
|
incorporation or organization)
|
|
|||
|
Strawinskylaan 913
|
|
|
||
|
Tower A, Level 9
|
|
|||
|
1077 XX Amsterdam
|
|
|||
|
The Netherlands
|
Not Applicable
|
|||
|
(Address of principal executive offices)
|
(Zip Code)
|
|||
|
|
|
|||
|
(31-20) 420-3191
|
||||
|
(Registrant's telephone number, including area code)
|
||||
|
|
||||
|
None
|
||||
|
(Former name, former address and former fiscal year, if changed since last report)
|
||||
|
Large accelerated filer
Q
|
Accelerated filer
o
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
CORE LABORATORIES N.V.
|
||
|
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2015
|
||
|
|
||
|
INDEX
|
||
|
|
||
|
PART I - FINANCIAL INFORMATION
|
||
|
|
|
Page
|
|
Item 1.
|
Financial Statements
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART II - OTHER INFORMATION
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
|
ASSETS
|
(Unaudited)
|
|
|
||||
|
CURRENT ASSETS:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
18,461
|
|
|
$
|
23,350
|
|
|
Accounts receivable, net of allowance for doubtful accounts of $3,746 and $3,397 at 2015 and 2014, respectively
|
152,448
|
|
|
197,163
|
|
||
|
Inventories
|
44,462
|
|
|
43,371
|
|
||
|
Prepaid expenses
|
11,013
|
|
|
14,246
|
|
||
|
Income taxes receivable
|
5,852
|
|
|
10,980
|
|
||
|
Other current assets
|
9,987
|
|
|
12,710
|
|
||
|
TOTAL CURRENT ASSETS
|
242,223
|
|
|
301,820
|
|
||
|
PROPERTY, PLANT AND EQUIPMENT, net
|
146,965
|
|
|
149,014
|
|
||
|
INTANGIBLES, net
|
13,523
|
|
|
10,642
|
|
||
|
GOODWILL
|
178,159
|
|
|
164,464
|
|
||
|
DEFERRED TAX ASSETS, net
|
10,087
|
|
|
3,876
|
|
||
|
OTHER ASSETS
|
44,148
|
|
|
45,837
|
|
||
|
TOTAL ASSETS
|
$
|
635,105
|
|
|
$
|
675,653
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
||
|
CURRENT LIABILITIES:
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
40,539
|
|
|
$
|
47,084
|
|
|
Accrued payroll and related costs
|
33,016
|
|
|
34,617
|
|
||
|
Taxes other than payroll and income
|
9,225
|
|
|
11,199
|
|
||
|
Unearned revenue
|
13,918
|
|
|
11,009
|
|
||
|
Income taxes payable
|
7,217
|
|
|
8,333
|
|
||
|
Other current liabilities
|
20,148
|
|
|
19,624
|
|
||
|
TOTAL CURRENT LIABILITIES
|
124,063
|
|
|
131,866
|
|
||
|
LONG-TERM DEBT
|
428,000
|
|
|
356,000
|
|
||
|
DEFERRED COMPENSATION
|
42,809
|
|
|
42,705
|
|
||
|
DEFERRED TAX LIABILITIES, net
|
2,505
|
|
|
7,210
|
|
||
|
OTHER LONG-TERM LIABILITIES
|
43,643
|
|
|
43,879
|
|
||
|
COMMITMENTS AND CONTINGENCIES (Note 6)
|
|
|
|
|
|
||
|
EQUITY (DEFICIT):
|
|
|
|
|
|||
|
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized,
none issued or outstanding
|
—
|
|
|
—
|
|
||
|
Common shares, EUR 0.02 par value;
200,000,000 shares authorized, 44,350,002 issued and 42,407,281 outstanding at 2015 and 45,600,002 issued and 43,636,984 outstanding at 2014 |
1,142
|
|
|
1,174
|
|
||
|
Additional paid-in capital
|
269
|
|
|
—
|
|
||
|
Retained earnings
|
236,041
|
|
|
415,906
|
|
||
|
Accumulated other comprehensive income (loss)
|
(11,901
|
)
|
|
(11,894
|
)
|
||
|
Treasury shares (at cost), 1,942,721 at 2015 and 1,963,018 at 2014
|
(237,795
|
)
|
|
(317,613
|
)
|
||
|
Total Core Laboratories N.V. shareholders' equity (deficit)
|
(12,244
|
)
|
|
87,573
|
|
||
|
Non-controlling interest
|
6,329
|
|
|
6,420
|
|
||
|
TOTAL EQUITY (DEFICIT)
|
(5,915
|
)
|
|
93,993
|
|
||
|
TOTAL LIABILITIES AND EQUITY
|
$
|
635,105
|
|
|
$
|
675,653
|
|
|
|
Three Months Ended
|
||||||
|
|
September 30,
|
||||||
|
|
2015
|
|
2014
|
||||
|
|
(Unaudited)
|
||||||
|
REVENUE:
|
|
|
|
||||
|
Services
|
$
|
150,128
|
|
|
$
|
203,578
|
|
|
Product sales
|
47,137
|
|
|
72,557
|
|
||
|
Total revenue
|
197,265
|
|
|
276,135
|
|
||
|
OPERATING EXPENSES:
|
|
|
|
|
|
||
|
Cost of services, exclusive of depreciation expense shown below
|
94,117
|
|
|
113,917
|
|
||
|
Cost of product sales, exclusive of depreciation expense shown below
|
34,933
|
|
|
53,010
|
|
||
|
General and administrative expense, exclusive of depreciation expense shown below
|
12,155
|
|
|
12,316
|
|
||
|
Depreciation
|
6,695
|
|
|
6,362
|
|
||
|
Amortization
|
215
|
|
|
483
|
|
||
|
Other (income) expense, net
|
2,332
|
|
|
927
|
|
||
|
OPERATING INCOME
|
46,818
|
|
|
89,120
|
|
||
|
Interest expense
|
3,471
|
|
|
2,561
|
|
||
|
Income before income tax expense
|
43,347
|
|
|
86,559
|
|
||
|
Income tax expense
|
9,753
|
|
|
19,909
|
|
||
|
Net income
|
33,594
|
|
|
66,650
|
|
||
|
Net income (loss) attributable to non-controlling interest
|
190
|
|
|
153
|
|
||
|
Net income attributable to Core Laboratories N.V.
|
$
|
33,404
|
|
|
$
|
66,497
|
|
|
EARNINGS PER SHARE INFORMATION:
|
|
|
|
|
|
||
|
Basic earnings per share attributable to Core Laboratories N.V.
|
$
|
0.79
|
|
|
$
|
1.51
|
|
|
|
|
|
|
||||
|
Diluted earnings per share attributable to Core Laboratories N.V.
|
$
|
0.78
|
|
|
$
|
1.50
|
|
|
|
|
|
|
||||
|
Cash dividends per share
|
$
|
0.55
|
|
|
$
|
0.50
|
|
|
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
|
|
|
|
|
|
||
|
Basic
|
42,517
|
|
|
44,152
|
|
||
|
Diluted
|
42,685
|
|
|
44,381
|
|
||
|
|
Nine Months Ended
|
||||||
|
|
September 30,
|
||||||
|
|
2015
|
|
2014
|
||||
|
|
(Unaudited)
|
||||||
|
REVENUE:
|
|
|
|
||||
|
Services
|
$
|
469,963
|
|
|
$
|
580,612
|
|
|
Product sales
|
144,834
|
|
|
225,988
|
|
||
|
Total revenue
|
614,797
|
|
|
806,600
|
|
||
|
OPERATING EXPENSES:
|
|
|
|
|
|
||
|
Cost of services, exclusive of depreciation expense shown below
|
295,374
|
|
|
336,194
|
|
||
|
Cost of product sales, exclusive of depreciation expense shown below
|
112,569
|
|
|
160,560
|
|
||
|
General and administrative expense, exclusive of depreciation expense shown below
|
37,463
|
|
|
33,983
|
|
||
|
Depreciation
|
19,792
|
|
|
18,731
|
|
||
|
Amortization
|
614
|
|
|
1,065
|
|
||
|
Other (income) expense, net
|
4,467
|
|
|
(14
|
)
|
||
|
Severance and other charges
|
7,090
|
|
|
—
|
|
||
|
OPERATING INCOME
|
137,428
|
|
|
256,081
|
|
||
|
Interest expense
|
8,990
|
|
|
7,718
|
|
||
|
Income before income tax expense
|
128,438
|
|
|
248,363
|
|
||
|
Income tax expense
|
29,100
|
|
|
56,464
|
|
||
|
Net income
|
99,338
|
|
|
191,899
|
|
||
|
Net income (loss) attributable to non-controlling interest
|
(91
|
)
|
|
604
|
|
||
|
Net income attributable to Core Laboratories N.V.
|
$
|
99,429
|
|
|
$
|
191,295
|
|
|
EARNINGS PER SHARE INFORMATION:
|
|
|
|
|
|
||
|
Basic earnings per share attributable to Core Laboratories N.V.
|
$
|
2.32
|
|
|
$
|
4.29
|
|
|
|
|
|
|
||||
|
Diluted earnings per share attributable to Core Laboratories N.V.
|
$
|
2.31
|
|
|
$
|
4.27
|
|
|
|
|
|
|
||||
|
Cash dividends per share
|
$
|
1.65
|
|
|
$
|
1.50
|
|
|
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
|
|
|
|
|
|
||
|
Basic
|
42,879
|
|
|
44,571
|
|
||
|
Diluted
|
43,038
|
|
|
44,823
|
|
||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
|
(Unaudited)
|
|
(Unaudited)
|
||||||||||||
|
Net income
|
$
|
33,594
|
|
|
$
|
66,650
|
|
|
$
|
99,338
|
|
|
$
|
191,899
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive income:
|
|
|
|
|
|
|
|
||||||||
|
Derivatives
|
|
|
|
|
|
|
|
||||||||
|
Gain (loss) in fair value of interest rate swaps
|
(1,475
|
)
|
|
—
|
|
|
(1,880
|
)
|
|
—
|
|
||||
|
Interest rate swap amounts reclassified to interest expense
|
246
|
|
|
—
|
|
|
734
|
|
|
—
|
|
||||
|
Income taxes on derivatives
|
455
|
|
|
—
|
|
|
822
|
|
|
—
|
|
||||
|
Total derivatives
|
(774
|
)
|
|
—
|
|
|
(324
|
)
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Pension and other postretirement benefit plans
|
|
|
|
|
|
|
|
||||||||
|
Prior service cost
|
|
|
|
|
|
|
|
||||||||
|
Amortization to net income of transition asset
|
(22
|
)
|
|
(21
|
)
|
|
(66
|
)
|
|
(65
|
)
|
||||
|
Amortization to net income of prior service cost
|
(21
|
)
|
|
2
|
|
|
(59
|
)
|
|
5
|
|
||||
|
Amortization to net income of actuarial loss
|
181
|
|
|
135
|
|
|
548
|
|
|
405
|
|
||||
|
Income taxes on pension and other postretirement benefit plans
|
(33
|
)
|
|
(29
|
)
|
|
(106
|
)
|
|
(86
|
)
|
||||
|
Total pension and other postretirement benefit plans
|
105
|
|
|
87
|
|
|
317
|
|
|
259
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Total other comprehensive income (loss)
|
(669
|
)
|
|
87
|
|
|
(7
|
)
|
|
259
|
|
||||
|
Comprehensive income
|
32,925
|
|
|
66,737
|
|
|
99,331
|
|
|
192,158
|
|
||||
|
Comprehensive income (loss) attributable to non-controlling interest
|
190
|
|
|
153
|
|
|
(91
|
)
|
|
604
|
|
||||
|
Comprehensive income attributable to Core Laboratories N.V.
|
$
|
32,735
|
|
|
$
|
66,584
|
|
|
$
|
99,422
|
|
|
$
|
191,554
|
|
|
|
Nine Months Ended
|
||||||
|
|
September 30,
|
||||||
|
|
2015
|
|
2014
|
||||
|
|
(Unaudited)
|
||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
||||
|
Net income
|
$
|
99,338
|
|
|
$
|
191,899
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
|
Stock-based compensation
|
15,964
|
|
|
15,497
|
|
||
|
Depreciation and amortization
|
20,406
|
|
|
19,796
|
|
||
|
(Increase) decrease in value of life insurance policies
|
2,190
|
|
|
(724
|
)
|
||
|
Deferred income taxes
|
(3,445
|
)
|
|
(190
|
)
|
||
|
Other non-cash items
|
1,259
|
|
|
1,069
|
|
||
|
Changes in assets and liabilities:
|
|
|
|
||||
|
Accounts receivable
|
43,775
|
|
|
(959
|
)
|
||
|
Inventories
|
(138
|
)
|
|
(3,053
|
)
|
||
|
Prepaid expenses and other current assets
|
8,039
|
|
|
(7,041
|
)
|
||
|
Other assets
|
2,061
|
|
|
1,529
|
|
||
|
Accounts payable
|
(10,864
|
)
|
|
(2,171
|
)
|
||
|
Accrued expenses
|
(8,582
|
)
|
|
(10,604
|
)
|
||
|
Unearned revenue
|
2,909
|
|
|
158
|
|
||
|
Other long-term liabilities
|
(3,142
|
)
|
|
453
|
|
||
|
Net cash provided by operating activities
|
169,770
|
|
|
205,659
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
||
|
Capital expenditures
|
(18,276
|
)
|
|
(27,624
|
)
|
||
|
Patents and other intangibles
|
(1,502
|
)
|
|
(753
|
)
|
||
|
Business acquisition, net of cash acquired
|
(13,824
|
)
|
|
(1,200
|
)
|
||
|
Proceeds from sale of assets
|
1,193
|
|
|
1,098
|
|
||
|
Premiums on life insurance
|
(2,210
|
)
|
|
(3,482
|
)
|
||
|
Net cash used in investing activities
|
(34,619
|
)
|
|
(31,961
|
)
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
||
|
Repayment of debt borrowings
|
(49,693
|
)
|
|
(57,157
|
)
|
||
|
Proceeds from debt borrowings
|
120,000
|
|
|
160,000
|
|
||
|
Excess tax benefits from stock-based compensation
|
180
|
|
|
2,680
|
|
||
|
Debt financing costs
|
(339
|
)
|
|
(1,054
|
)
|
||
|
Non-controlling interest - dividend
|
—
|
|
|
(393
|
)
|
||
|
Dividends paid
|
(70,933
|
)
|
|
(67,153
|
)
|
||
|
Repurchase of common shares
|
(139,255
|
)
|
|
(210,402
|
)
|
||
|
Net cash used in financing activities
|
(140,040
|
)
|
|
(173,479
|
)
|
||
|
NET CHANGE IN CASH AND CASH EQUIVALENTS
|
(4,889
|
)
|
|
219
|
|
||
|
CASH AND CASH EQUIVALENTS, beginning of period
|
23,350
|
|
|
25,088
|
|
||
|
CASH AND CASH EQUIVALENTS, end of period
|
$
|
18,461
|
|
|
$
|
25,307
|
|
|
|
September 30,
2015 |
|
June 30,
2015 |
|
December 31,
2014 |
||||||
|
Finished goods
|
$
|
30,654
|
|
|
$
|
34,298
|
|
|
$
|
32,249
|
|
|
Parts and materials
|
10,790
|
|
|
10,817
|
|
|
9,147
|
|
|||
|
Work in progress
|
3,018
|
|
|
2,470
|
|
|
1,975
|
|
|||
|
Total inventories
|
$
|
44,462
|
|
|
$
|
47,585
|
|
|
$
|
43,371
|
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
|
Senior notes
|
$
|
150,000
|
|
|
$
|
150,000
|
|
|
Credit facility
|
278,000
|
|
|
206,000
|
|
||
|
Long-term debt
|
$
|
428,000
|
|
|
$
|
356,000
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
Service cost
|
$
|
453
|
|
|
$
|
361
|
|
|
$
|
1,356
|
|
|
$
|
1,103
|
|
|
Interest cost
|
301
|
|
|
439
|
|
|
904
|
|
|
1,341
|
|
||||
|
Expected return on plan assets
|
(249
|
)
|
|
(326
|
)
|
|
(748
|
)
|
|
(995
|
)
|
||||
|
Amortization of transition asset
|
(22
|
)
|
|
(21
|
)
|
|
(66
|
)
|
|
(65
|
)
|
||||
|
Amortization of prior service cost
|
(21
|
)
|
|
2
|
|
|
(59
|
)
|
|
5
|
|
||||
|
Amortization of actuarial loss
|
181
|
|
|
135
|
|
|
548
|
|
|
405
|
|
||||
|
Net periodic pension cost
|
$
|
643
|
|
|
$
|
590
|
|
|
$
|
1,935
|
|
|
$
|
1,794
|
|
|
|
Common Shares
|
|
Additional Paid-In Capital
|
|
Retained Earnings
|
|
Accumulated
Other Comprehensive Income (Loss) |
|
Treasury Stock
|
|
Non-Controlling Interest
|
|
Total Equity
|
||||||||||||||
|
December 31, 2014
|
$
|
1,174
|
|
|
$
|
—
|
|
|
$
|
415,906
|
|
|
$
|
(11,894
|
)
|
|
$
|
(317,613
|
)
|
|
$
|
6,420
|
|
|
$
|
93,993
|
|
|
Stock based-awards
|
—
|
|
|
3,181
|
|
|
(2,094
|
)
|
|
—
|
|
|
14,877
|
|
|
—
|
|
|
15,964
|
|
|||||||
|
Tax benefit of stock-based awards issued
|
—
|
|
|
180
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
180
|
|
|||||||
|
Repurchase of common shares
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(144,450
|
)
|
|
—
|
|
|
(144,450
|
)
|
|||||||
|
Dividends paid
|
—
|
|
|
—
|
|
|
(70,933
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(70,933
|
)
|
|||||||
|
Cancellation of common shares
|
(32
|
)
|
|
(3,092
|
)
|
|
(206,267
|
)
|
|
—
|
|
|
209,391
|
|
|
—
|
|
|
—
|
|
|||||||
|
Amortization of deferred pension costs, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
317
|
|
|
—
|
|
|
—
|
|
|
317
|
|
|||||||
|
Interest rate swaps
|
—
|
|
|
—
|
|
|
—
|
|
|
(324
|
)
|
|
—
|
|
|
—
|
|
|
(324
|
)
|
|||||||
|
Net income (loss)
|
—
|
|
|
—
|
|
|
99,429
|
|
|
—
|
|
|
—
|
|
|
(91
|
)
|
|
99,338
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
September 30, 2015
|
$
|
1,142
|
|
|
$
|
269
|
|
|
$
|
236,041
|
|
|
$
|
(11,901
|
)
|
|
$
|
(237,795
|
)
|
|
$
|
6,329
|
|
|
$
|
(5,915
|
)
|
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
|
Transition asset
|
$
|
15
|
|
|
$
|
65
|
|
|
Prior service cost
|
674
|
|
|
718
|
|
||
|
Unrecognized net actuarial loss
|
(11,184
|
)
|
|
(11,595
|
)
|
||
|
Fair value of derivatives, net of tax
|
(1,406
|
)
|
|
(1,082
|
)
|
||
|
Total accumulated other comprehensive income (loss)
|
$
|
(11,901
|
)
|
|
$
|
(11,894
|
)
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||
|
|
September 30,
|
|
September 30,
|
||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
|
Weighted average basic common shares outstanding
|
42,517
|
|
|
44,152
|
|
|
42,879
|
|
|
44,571
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
||||
|
Performance shares
|
114
|
|
|
121
|
|
|
95
|
|
|
110
|
|
|
Restricted stock
|
54
|
|
|
108
|
|
|
64
|
|
|
142
|
|
|
Weighted average diluted common and potential common shares outstanding
|
42,685
|
|
|
44,381
|
|
|
43,038
|
|
|
44,823
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
Sale of assets
|
$
|
(100
|
)
|
|
$
|
(442
|
)
|
|
$
|
(362
|
)
|
|
$
|
(740
|
)
|
|
Results of non-consolidated subsidiaries
|
(131
|
)
|
|
(165
|
)
|
|
(211
|
)
|
|
(295
|
)
|
||||
|
Foreign exchange
|
2,612
|
|
|
1,858
|
|
|
4,454
|
|
|
2,158
|
|
||||
|
Rents and royalties
|
(115
|
)
|
|
(209
|
)
|
|
(370
|
)
|
|
(656
|
)
|
||||
|
Other, net
|
66
|
|
|
(115
|
)
|
|
956
|
|
|
(481
|
)
|
||||
|
Total other (income) expense, net
|
$
|
2,332
|
|
|
$
|
927
|
|
|
$
|
4,467
|
|
|
$
|
(14
|
)
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
Angolan Kwanza
|
$
|
311
|
|
|
$
|
—
|
|
|
$
|
819
|
|
|
$
|
(3
|
)
|
|
Australian Dollar
|
3
|
|
|
104
|
|
|
186
|
|
|
166
|
|
||||
|
British Pound
|
173
|
|
|
770
|
|
|
285
|
|
|
496
|
|
||||
|
Canadian Dollar
|
549
|
|
|
903
|
|
|
1,772
|
|
|
1,071
|
|
||||
|
Euro
|
615
|
|
|
(449
|
)
|
|
(145
|
)
|
|
(446
|
)
|
||||
|
Indonesian Rupiah
|
219
|
|
|
82
|
|
|
381
|
|
|
48
|
|
||||
|
Malaysian Ringgit
|
361
|
|
|
77
|
|
|
533
|
|
|
90
|
|
||||
|
Nigerian Naira
|
238
|
|
|
48
|
|
|
557
|
|
|
118
|
|
||||
|
Russian Ruble
|
(32
|
)
|
|
162
|
|
|
(37
|
)
|
|
202
|
|
||||
|
Other currencies, net
|
175
|
|
|
161
|
|
|
103
|
|
|
416
|
|
||||
|
Total (gain) loss, net
|
$
|
2,612
|
|
|
$
|
1,858
|
|
|
$
|
4,454
|
|
|
$
|
2,158
|
|
|
|
Fair Value of Derivatives
|
|
|
||||||
|
|
September 30, 2015
|
|
December 31, 2014
|
|
Balance Sheet Classification
|
||||
|
Derivatives designated as hedges:
|
|
|
|
|
|
||||
|
5 year interest rate swap
|
$
|
667
|
|
|
$
|
201
|
|
|
Other long-term liabilities
|
|
10 year interest rate swap
|
1,561
|
|
|
881
|
|
|
Other long-term liabilities
|
||
|
|
$
|
2,228
|
|
|
$
|
1,082
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
||||||||||||
|
|
September 30, 2015
|
|
September 30, 2014
|
|
September 30, 2015
|
|
September 30, 2014
|
|
Income Statement Classification
|
||||||||
|
Derivatives designated as hedges:
|
|
|
|
|
|
|
|
|
|
||||||||
|
5 year interest rate swap
|
$
|
98
|
|
|
$
|
—
|
|
|
$
|
293
|
|
|
$
|
—
|
|
|
Increase to interest expense
|
|
10 year interest rate swap
|
148
|
|
|
—
|
|
|
441
|
|
|
—
|
|
|
Increase to interest expense
|
||||
|
|
$
|
246
|
|
|
$
|
—
|
|
|
$
|
734
|
|
|
$
|
—
|
|
|
|
|
|
|
|
Fair Value Measurement at
|
||||||||||||
|
|
|
|
September 30, 2015
|
||||||||||||
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Deferred compensation trust assets
(1)
|
$
|
23,058
|
|
|
$
|
—
|
|
|
$
|
23,058
|
|
|
$
|
—
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||
|
Deferred compensation plan
|
$
|
28,114
|
|
|
$
|
—
|
|
|
$
|
28,114
|
|
|
$
|
—
|
|
|
5 year interest rate swap
|
667
|
|
|
—
|
|
|
667
|
|
|
—
|
|
||||
|
10 year interest rate swap
|
1,561
|
|
|
—
|
|
|
1,561
|
|
|
—
|
|
||||
|
|
$
|
30,342
|
|
|
$
|
—
|
|
|
$
|
30,342
|
|
|
$
|
—
|
|
|
|
|
|
Fair Value Measurement at
|
||||||||||||
|
|
|
|
December 31, 2014
|
||||||||||||
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Deferred compensation trust assets
(1)
|
$
|
24,199
|
|
|
$
|
—
|
|
|
$
|
24,199
|
|
|
$
|
—
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||||||
|
Deferred compensation plan
|
$
|
29,153
|
|
|
$
|
—
|
|
|
$
|
29,153
|
|
|
$
|
—
|
|
|
5 year interest rate swap
|
201
|
|
|
—
|
|
|
201
|
|
|
—
|
|
||||
|
10 year interest rate swap
|
881
|
|
|
—
|
|
|
881
|
|
|
—
|
|
||||
|
|
$
|
30,235
|
|
|
$
|
—
|
|
|
$
|
30,235
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(1) Trust assets consist of the cash surrender value of life insurance policies intended to assist in the funding of the deferred compensation plan and are included in Other assets in the Balance Sheet.
|
|||||||||||||||
|
•
|
Reservoir Description:
Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
|
|
•
|
Production Enhancement:
Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
|
|
•
|
Reservoir Management:
Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.
|
|
|
Reservoir Description
|
|
Production Enhancement
|
|
Reservoir Management
|
|
Corporate & Other
1
|
|
Consolidated
|
||||||||||
|
Three Months Ended September 30, 2015
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Revenue from unaffiliated clients
|
$
|
117,943
|
|
|
$
|
64,918
|
|
|
$
|
14,404
|
|
|
$
|
—
|
|
|
$
|
197,265
|
|
|
Inter-segment revenue
|
1,770
|
|
|
140
|
|
|
37
|
|
|
(1,947
|
)
|
|
—
|
|
|||||
|
Segment operating income (loss)
|
30,338
|
|
|
11,367
|
|
|
4,796
|
|
|
317
|
|
|
46,818
|
|
|||||
|
Total assets (at end of period)
|
334,892
|
|
|
210,209
|
|
|
24,320
|
|
|
65,684
|
|
|
635,105
|
|
|||||
|
Capital expenditures
|
5,224
|
|
|
309
|
|
|
7
|
|
|
426
|
|
|
5,966
|
|
|||||
|
Depreciation and amortization
|
4,287
|
|
|
1,614
|
|
|
401
|
|
|
608
|
|
|
6,910
|
|
|||||
|
Three Months Ended September 30, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenue from unaffiliated clients
|
$
|
131,380
|
|
|
$
|
122,161
|
|
|
$
|
22,594
|
|
|
$
|
—
|
|
|
$
|
276,135
|
|
|
Inter-segment revenue
|
4,734
|
|
|
52,916
|
|
|
1,422
|
|
|
(59,072
|
)
|
|
—
|
|
|||||
|
Segment operating income (loss)
|
35,377
|
|
|
45,735
|
|
|
7,553
|
|
|
455
|
|
|
89,120
|
|
|||||
|
Total assets (at end of period)
|
317,741
|
|
|
277,320
|
|
|
33,646
|
|
|
56,425
|
|
|
685,132
|
|
|||||
|
Capital expenditures
|
4,577
|
|
|
2,678
|
|
|
2,021
|
|
|
(1,439
|
)
|
|
7,837
|
|
|||||
|
Depreciation and amortization
|
4,158
|
|
|
1,830
|
|
|
350
|
|
|
507
|
|
|
6,845
|
|
|||||
|
Nine Months Ended September 30, 2015
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Revenue from unaffiliated clients
|
$
|
358,613
|
|
|
$
|
210,652
|
|
|
$
|
45,532
|
|
|
$
|
—
|
|
|
$
|
614,797
|
|
|
Inter-segment revenue
|
6,957
|
|
|
1,509
|
|
|
244
|
|
|
(8,710
|
)
|
|
—
|
|
|||||
|
Segment operating income (loss)
|
89,812
|
|
|
35,666
|
|
|
12,114
|
|
|
(164
|
)
|
|
137,428
|
|
|||||
|
Total assets
|
334,892
|
|
|
210,209
|
|
|
24,320
|
|
|
65,684
|
|
|
635,105
|
|
|||||
|
Capital expenditures
|
13,958
|
|
|
2,821
|
|
|
273
|
|
|
1,224
|
|
|
18,276
|
|
|||||
|
Depreciation and amortization
|
12,302
|
|
|
5,024
|
|
|
1,254
|
|
|
1,826
|
|
|
20,406
|
|
|||||
|
Nine Months Ended September 30, 2014
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Revenue from unaffiliated clients
|
$
|
387,225
|
|
|
$
|
343,434
|
|
|
$
|
75,941
|
|
|
$
|
—
|
|
|
$
|
806,600
|
|
|
Inter-segment revenue
|
10,266
|
|
|
54,097
|
|
|
2,189
|
|
|
(66,552
|
)
|
|
—
|
|
|||||
|
Segment operating income (loss)
|
106,571
|
|
|
120,597
|
|
|
27,821
|
|
|
1,092
|
|
|
256,081
|
|
|||||
|
Total assets
|
317,741
|
|
|
277,320
|
|
|
33,646
|
|
|
56,425
|
|
|
685,132
|
|
|||||
|
Capital expenditures
|
15,673
|
|
|
5,508
|
|
|
2,388
|
|
|
4,055
|
|
|
27,624
|
|
|||||
|
Depreciation and amortization
|
11,941
|
|
|
5,605
|
|
|
955
|
|
|
1,295
|
|
|
19,796
|
|
|||||
|
•
|
Reservoir Description:
Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
|
|
•
|
Production Enhancement:
Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
|
|
•
|
Reservoir Management:
Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.
|
|
|
Three Months Ended September 30,
|
|
$ Change
|
% Change
|
|||||||||||||||
|
|
2015
|
|
2014
|
|
2015/2014
|
|
2015/2014
|
|
|||||||||||
|
REVENUE:
|
|
|
|
|
|
||||||||||||||
|
Services
|
$
|
150,128
|
|
|
76
|
%
|
|
$
|
203,578
|
|
|
74
|
%
|
|
$
|
(53,450
|
)
|
(26
|
)%
|
|
Product sales
|
47,137
|
|
|
24
|
%
|
|
72,557
|
|
|
26
|
%
|
|
(25,420
|
)
|
(35
|
)%
|
|||
|
Total revenue
|
197,265
|
|
|
100
|
%
|
|
276,135
|
|
|
100
|
%
|
|
(78,870
|
)
|
(29
|
)%
|
|||
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Cost of services, exclusive of depreciation expense shown below*
|
94,117
|
|
|
63
|
%
|
|
113,917
|
|
|
56
|
%
|
|
(19,800
|
)
|
(17
|
)%
|
|||
|
Cost of product sales, exclusive of depreciation expense shown below*
|
34,933
|
|
|
74
|
%
|
|
53,010
|
|
|
73
|
%
|
|
(18,077
|
)
|
(34
|
)%
|
|||
|
Total cost of services and product sales
|
129,050
|
|
|
65
|
%
|
|
166,927
|
|
|
60
|
%
|
|
(37,877
|
)
|
(23
|
)%
|
|||
|
General and administrative expense
|
12,155
|
|
|
6
|
%
|
|
12,316
|
|
|
4
|
%
|
|
(161
|
)
|
(1
|
)%
|
|||
|
Depreciation and amortization
|
6,910
|
|
|
4
|
%
|
|
6,845
|
|
|
2
|
%
|
|
65
|
|
1
|
%
|
|||
|
Other (income) expense, net
|
2,332
|
|
|
1
|
%
|
|
927
|
|
|
0
|
%
|
|
1,405
|
|
NM
|
|
|||
|
Operating income
|
46,818
|
|
|
24
|
%
|
|
89,120
|
|
|
32
|
%
|
|
(42,302
|
)
|
(47
|
)%
|
|||
|
Interest expense
|
3,471
|
|
|
2
|
%
|
|
2,561
|
|
|
1
|
%
|
|
910
|
|
36
|
%
|
|||
|
Income before income tax expense
|
43,347
|
|
|
22
|
%
|
|
86,559
|
|
|
31
|
%
|
|
(43,212
|
)
|
(50
|
)%
|
|||
|
Income tax expense
|
9,753
|
|
|
5
|
%
|
|
19,909
|
|
|
7
|
%
|
|
(10,156
|
)
|
(51
|
)%
|
|||
|
Net income
|
33,594
|
|
|
17
|
%
|
|
66,650
|
|
|
24
|
%
|
|
(33,056
|
)
|
(50
|
)%
|
|||
|
Net income (loss) attributable to non-controlling interest
|
190
|
|
|
0
|
%
|
|
153
|
|
|
0
|
%
|
|
37
|
|
24
|
%
|
|||
|
Net income attributable to Core Laboratories N.V.
|
$
|
33,404
|
|
|
17
|
%
|
|
$
|
66,497
|
|
|
24
|
%
|
|
$
|
(33,093
|
)
|
(50
|
)%
|
|
"NM" means not meaningful
|
|
|
|
||||||||||||||||
|
* Percentage based on applicable revenue rather than total revenue.
|
|
|
|
|
|
|
|
||||||||||||
|
|
Nine Months Ended September 30,
|
|
$ Change
|
% Change
|
|||||||||||||||
|
|
2015
|
|
2014
|
|
2015/2014
|
|
2015/2014
|
||||||||||||
|
REVENUE:
|
|
|
|
|
|||||||||||||||
|
Services
|
$
|
469,963
|
|
|
76
|
%
|
|
$
|
580,612
|
|
|
72
|
%
|
|
$
|
(110,649
|
)
|
(19
|
)%
|
|
Product sales
|
144,834
|
|
|
24
|
%
|
|
225,988
|
|
|
28
|
%
|
|
(81,154
|
)
|
(36
|
)%
|
|||
|
Total revenue
|
614,797
|
|
|
100
|
%
|
|
806,600
|
|
|
100
|
%
|
|
(191,803
|
)
|
(24
|
)%
|
|||
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Cost of services, exclusive of depreciation expense shown below*
|
295,374
|
|
|
63
|
%
|
|
336,194
|
|
|
58
|
%
|
|
(40,820
|
)
|
(12
|
)%
|
|||
|
Cost of product sales, exclusive of depreciation expense shown below*
|
112,569
|
|
|
78
|
%
|
|
160,560
|
|
|
71
|
%
|
|
(47,991
|
)
|
(30
|
)%
|
|||
|
Total cost of services and product sales
|
407,943
|
|
|
66
|
%
|
|
496,754
|
|
|
62
|
%
|
|
(88,811
|
)
|
(18
|
)%
|
|||
|
General and administrative expense
|
37,463
|
|
|
6
|
%
|
|
33,983
|
|
|
4
|
%
|
|
3,480
|
|
10
|
%
|
|||
|
Depreciation and amortization
|
20,406
|
|
|
3
|
%
|
|
19,796
|
|
|
2
|
%
|
|
610
|
|
3
|
%
|
|||
|
Other (income), net
|
4,467
|
|
|
1
|
%
|
|
(14
|
)
|
|
0
|
%
|
|
4,481
|
|
NM
|
|
|||
|
Severance and other charges
|
7,090
|
|
|
1
|
%
|
|
—
|
|
|
0
|
%
|
|
7,090
|
|
NM
|
|
|||
|
Operating income
|
137,428
|
|
|
22
|
%
|
|
256,081
|
|
|
32
|
%
|
|
(118,653
|
)
|
(46
|
)%
|
|||
|
Interest expense
|
8,990
|
|
|
1
|
%
|
|
7,718
|
|
|
1
|
%
|
|
1,272
|
|
16
|
%
|
|||
|
Income before income tax expense
|
128,438
|
|
|
21
|
%
|
|
248,363
|
|
|
31
|
%
|
|
(119,925
|
)
|
(48
|
)%
|
|||
|
Income tax expense
|
29,100
|
|
|
5
|
%
|
|
56,464
|
|
|
7
|
%
|
|
(27,364
|
)
|
(48
|
)%
|
|||
|
Net income
|
99,338
|
|
|
16
|
%
|
|
191,899
|
|
|
24
|
%
|
|
(92,561
|
)
|
(48
|
)%
|
|||
|
Net income (loss) attributable to non-controlling interest
|
(91
|
)
|
|
0
|
%
|
|
604
|
|
|
0
|
%
|
|
(695
|
)
|
(115
|
)%
|
|||
|
Net income attributable to Core Laboratories N.V.
|
$
|
99,429
|
|
|
16
|
%
|
|
$
|
191,295
|
|
|
24
|
%
|
|
$
|
(91,866
|
)
|
(48
|
)%
|
|
"NM" means not meaningful
|
|
|
|
||||||||||||||||
|
* Percentage based on applicable revenue rather than total revenue.
|
|
|
|
|
|
||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
Sale of assets
|
$
|
(100
|
)
|
|
$
|
(442
|
)
|
|
$
|
(362
|
)
|
|
$
|
(740
|
)
|
|
Results of non-consolidated subsidiaries
|
(131
|
)
|
|
(165
|
)
|
|
(211
|
)
|
|
(295
|
)
|
||||
|
Foreign exchange
|
2,612
|
|
|
1,858
|
|
|
4,454
|
|
|
2,158
|
|
||||
|
Rents and royalties
|
(115
|
)
|
|
(209
|
)
|
|
(370
|
)
|
|
(656
|
)
|
||||
|
Other, net
|
66
|
|
|
(115
|
)
|
|
956
|
|
|
(481
|
)
|
||||
|
Total other (income) expense, net
|
$
|
2,332
|
|
|
$
|
927
|
|
|
$
|
4,467
|
|
|
$
|
(14
|
)
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
September 30,
|
|
September 30,
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
|
Angolan Kwanza
|
$
|
311
|
|
|
$
|
—
|
|
|
$
|
819
|
|
|
$
|
(3
|
)
|
|
Australian Dollar
|
3
|
|
|
104
|
|
|
186
|
|
|
166
|
|
||||
|
British Pound
|
173
|
|
|
770
|
|
|
285
|
|
|
496
|
|
||||
|
Canadian Dollar
|
549
|
|
|
903
|
|
|
1,772
|
|
|
1,071
|
|
||||
|
Euro
|
615
|
|
|
(449
|
)
|
|
(145
|
)
|
|
(446
|
)
|
||||
|
Indonesian Rupiah
|
219
|
|
|
82
|
|
|
381
|
|
|
48
|
|
||||
|
Malaysian Ringgit
|
361
|
|
|
77
|
|
|
533
|
|
|
90
|
|
||||
|
Nigerian Naira
|
238
|
|
|
48
|
|
|
557
|
|
|
118
|
|
||||
|
Russian Ruble
|
(32
|
)
|
|
162
|
|
|
(37
|
)
|
|
202
|
|
||||
|
Other currencies, net
|
175
|
|
|
161
|
|
|
103
|
|
|
416
|
|
||||
|
Total (gain) loss, net
|
$
|
2,612
|
|
|
$
|
1,858
|
|
|
$
|
4,454
|
|
|
$
|
2,158
|
|
|
|
|
Three Months Ended September 30,
|
|
$ Change
|
% Change
|
|
Three Months Ended June 30,
|
|
$ Change
|
% Change
|
||||||||||||||
|
|
|
2015
|
|
2014
|
|
2015/2014
|
2015/2014
|
|
2015
|
|
Q3/Q2
|
Q3/Q2
|
||||||||||||
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Reservoir Description
|
|
$
|
117,943
|
|
|
$
|
131,380
|
|
|
$
|
(13,437
|
)
|
(10
|
)%
|
|
$
|
118,911
|
|
|
$
|
(968
|
)
|
(1
|
)%
|
|
Production Enhancement
|
|
64,918
|
|
|
122,161
|
|
|
(57,243
|
)
|
(47
|
)%
|
|
70,589
|
|
|
(5,671
|
)
|
(8
|
)%
|
|||||
|
Reservoir Management
|
|
14,404
|
|
|
22,594
|
|
|
(8,190
|
)
|
(36
|
)%
|
|
14,389
|
|
|
15
|
|
0
|
%
|
|||||
|
Consolidated
|
|
$
|
197,265
|
|
|
$
|
276,135
|
|
|
$
|
(78,870
|
)
|
(29
|
)%
|
|
$
|
203,889
|
|
|
$
|
(6,624
|
)
|
(3
|
)%
|
|
Operating income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Reservoir Description
|
|
$
|
30,338
|
|
|
$
|
35,377
|
|
|
$
|
(5,039
|
)
|
(14
|
)%
|
|
$
|
30,944
|
|
|
$
|
(606
|
)
|
(2
|
)%
|
|
Production Enhancement
|
|
11,367
|
|
|
45,735
|
|
|
(34,368
|
)
|
(75
|
)%
|
|
14,376
|
|
|
(3,009
|
)
|
(21
|
)%
|
|||||
|
Reservoir Management
|
|
4,796
|
|
|
7,553
|
|
|
(2,757
|
)
|
(37
|
)%
|
|
3,452
|
|
|
1,344
|
|
39
|
%
|
|||||
|
Corporate and Other
1
|
|
317
|
|
|
455
|
|
|
(138
|
)
|
NM
|
|
|
(879
|
)
|
|
1,196
|
|
NM
|
|
|||||
|
Consolidated
|
|
$
|
46,818
|
|
|
$
|
89,120
|
|
|
$
|
(42,302
|
)
|
(47
|
)%
|
|
$
|
47,893
|
|
|
$
|
(1,075
|
)
|
(2
|
)%
|
|
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
|
||||||||||||||||||||||||
|
"NM" means not meaningful
|
|
|
|
|
|
|||||||||||||||||||
|
|
|
Nine Months Ended September 30,
|
|
$ Change
|
% Change
|
|||||||||
|
|
|
2015
|
|
2014
|
|
2015/2014
|
2015/2014
|
|||||||
|
Revenue:
|
|
(Unaudited)
|
|
|
|
|
||||||||
|
Reservoir Description
|
|
$
|
358,613
|
|
|
$
|
387,225
|
|
|
$
|
(28,612
|
)
|
(7
|
)%
|
|
Production Enhancement
|
|
210,652
|
|
|
343,434
|
|
|
(132,782
|
)
|
(39
|
)%
|
|||
|
Reservoir Management
|
|
45,532
|
|
|
75,941
|
|
|
(30,409
|
)
|
(40
|
)%
|
|||
|
Consolidated
|
|
$
|
614,797
|
|
|
$
|
806,600
|
|
|
$
|
(191,803
|
)
|
(24
|
)%
|
|
Operating income (loss):
|
|
|
|
|
|
|
|
|
|
|
||||
|
Reservoir Description
|
|
$
|
89,812
|
|
|
$
|
106,571
|
|
|
$
|
(16,759
|
)
|
(16
|
)%
|
|
Production Enhancement
|
|
35,666
|
|
|
120,597
|
|
|
(84,931
|
)
|
(70
|
)%
|
|||
|
Reservoir Management
|
|
12,114
|
|
|
27,821
|
|
|
(15,707
|
)
|
(56
|
)%
|
|||
|
Corporate and Other
1
|
|
(164
|
)
|
|
1,092
|
|
|
(1,256
|
)
|
NM
|
|
|||
|
Consolidated
|
|
$
|
137,428
|
|
|
$
|
256,081
|
|
|
$
|
(118,653
|
)
|
(46
|
)%
|
|
(1) "Corporate and Other" represents those items that are not directly related to a particular segment
|
||||||||||||||
|
"NM" means not meaningful
|
||||||||||||||
|
|
Nine Months Ended September 30,
|
|
% Change
|
|||||||
|
|
2015
|
|
2014
|
|
2015/2014
|
|||||
|
Free cash flow calculation:
|
|
|
|
|
||||||
|
Net cash provided by operating activities
|
$
|
169,770
|
|
|
$
|
205,659
|
|
|
(17
|
)%
|
|
Less: cash paid for capital expenditures
|
18,276
|
|
|
27,624
|
|
|
(34
|
)%
|
||
|
Free cash flow
|
$
|
151,494
|
|
|
$
|
178,035
|
|
|
(15
|
)%
|
|
|
Nine Months Ended September 30,
|
|
% Change
|
|||||||
|
|
2015
|
|
2014
|
|
2015/2014
|
|||||
|
Cash provided by/(used in):
|
|
|
|
|
||||||
|
Operating activities
|
$
|
169,770
|
|
|
$
|
205,659
|
|
|
(17
|
)%
|
|
Investing activities
|
(34,619
|
)
|
|
(31,961
|
)
|
|
8
|
%
|
||
|
Financing activities
|
(140,040
|
)
|
|
(173,479
|
)
|
|
(19
|
)%
|
||
|
Net change in cash and cash equivalents
|
$
|
(4,889
|
)
|
|
$
|
219
|
|
|
(2,332
|
)%
|
|
Period
|
|
Total Number of Shares Purchased
|
|
Average Price Paid Per Share
|
|
Total Number of Shares Purchased as Part of a Publicly Announced Program
|
|
Maximum Number of Shares That May Yet be Purchased Under the Program
(3)(4)
|
|||
|
July 31, 2015
|
|
132,449
|
|
|
$
|
109.09
|
|
|
132,449
|
|
1,485,895
|
|
August 31, 2015 (1)
|
|
65,551
|
|
|
107.68
|
|
|
65,551
|
|
2,547,769
|
|
|
September 30, 2015 (2)
|
|
70,594
|
|
|
101.29
|
|
|
70,594
|
|
2,492,279
|
|
|
Total
|
|
268,594
|
|
|
$
|
106.70
|
|
|
268,594
|
|
|
|
Exhibit No.
|
|
Exhibit Title
|
Incorporated by reference from the following documents
|
|
3.1
|
-
|
Articles of Association of Core Laboratories N.V., as amended in 2012 (including English translation)
|
Exhibit 3.1 filed on February 19, 2013 with 2012 10-K (File No. 001-14273)
|
|
10.1
|
-
|
Amendment No. 1 to the Sixth Amended and Restated Credit Agreement between Core Laboratories N.V. and Core Laboratories (U.S.) Interests Holdings, Inc., as borrowers, and Bank of America, N.A. as Administrative Agent, Swing Line Lender and L/C Issuer.
|
Form 8-K, March 16, 2015 (File No. 001-14273)
|
|
31.1
|
-
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
|
31.2
|
-
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
|
32.1
|
-
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Furnished herewith
|
|
32.2
|
-
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Furnished herewith
|
|
101.INS
|
-
|
XBRL Instance Document
|
Filed herewith
|
|
101.SCH
|
-
|
XBRL Schema Document
|
Filed herewith
|
|
101.CAL
|
-
|
XBRL Calculation Linkbase Document
|
Filed herewith
|
|
101.LAB
|
-
|
XBRL Label Linkbase Document
|
Filed herewith
|
|
101.PRE
|
-
|
XBRL Presentation Linkbase Document
|
Filed herewith
|
|
101.DEF
|
-
|
XBRL Definition Linkbase Document
|
Filed herewith
|
|
|
CORE LABORATORIES N.V.
|
||
|
|
|
|
|
|
Date:
|
October 23, 2015
|
By:
|
/s/ Richard L. Bergmark
|
|
|
|
Richard L. Bergmark
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
(Duly Authorized Officer and
|
|
|
|
|
Principal Financial Officer)
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|